Amgen is advancing a long-acting GLP1 analogue (MariTide), Boehringer Ingelheim and Zealand are developing a GLP1 and glucagon dual agonist (survodutide), and companies like Viking (VK2735), Altimmune (pemvidutide), and others are testing their own GLP1, dual, or oral small-molecule programmes
The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning
In the highest dose cohort, participants lost an average of 8.4% of their body weight
It achieves this by providing complimentary access to key USP resources, including the United States PharmacopeiaNational Formulary (USP-NF) and our library of self-paced online education courses to eligible stakeholders
*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
